Mark Fleming, MD, Virginia Oncology Associates (US Oncology Network), discusses the novel PET imaging agent 18F-rhPSMA-7.3 and findings with the agent in the phase 3 SPOTLIGHT trial. Results from the study presented by Fleming at the 2022 AUA Annual Meeting showed that PET imaging with 18F-rhPSMA-7.3 frequently led to post-scan disease upstaging compared with baseline conventional imaging in men with prostate cancer recurrence.
Enhancing the quality of bladder cancer care in the community setting
August 5th 2023Suzanne Merrill, MD, recaps the BCAN 2023 Think Tank session she co-chaired that covered prehabilitation programs, urinary diversion management, and other focal areas aimed at enhancing the quality of bladder cancer care in the community.
BCAN session to highlight epigenetics and response to immunotherapy in bladder cancer
August 3rd 2023"I'm really optimistic that the session we are conducting will provide some recommendations [and] some ideas that will help us think about utilizing epigenetic therapies in a very evidence-based way," says Ania Woloszynska, PhD.
2 Clarke Drive
Cranbury, NJ 08512